Newsfeeds Archive - Spark Newswire

4 minute read

Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD’s Perceived Risks, Knowledge Gaps, Surveys & More

January 15, 2:38 PM

Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.

ATAI

1 minute read

News

IntelGenx Announces Co-Development And Commercialization Of Cannabinoid-Infused VersaFilm Products With Tilray

By Benzinga Newsdesk

November 6, 9:34 AM

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it and Tilray Brands Inc. ("Tilray") have entered into a further amendment (the "Second Amendment") to their November 2018

IGXT

2 minute read

IntelGenx Q2 2023: Revenue Decline 67%, Operating Costs Rise, What About Net Loss?

By Nicolas Jose Rodriguez

August 14, 10:54 PM

IntelGenx Technologies Corp. (TSX: IGX) (OTC: IGXT), a drug delivery company focused on the development and manufacturing of pharmaceutical films, reported its financial results on Monday for the second quarter ending on June 30, 2023.

IGXT

3 minute read

Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More

By Lara Goldstein

May 15, 5:30 PM

Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths Ph.D. Professorship Fund.

ATAI

1 minute read

FDA Gives Nod To IntelGenx’s Migraine Solution As Revenues Plunge 32%; Q1 Results Report

By Nicolas Jose Rodriguez

May 11, 6:33 PM

IntelGenx Technologies Corp. (OTC: IGXT) reported on Thursday a 32% decrease in total revenues for the first quarter of 2023, amounting to $162,000 as compared to $237,000 in the same

IGXT

3 minute read

Psyched: Canada’s Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More

By Lara Goldstein

April 5, 9:57 AM

Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin is a constitutional right under the Canadian Charter of Rights and Freedoms.

IGXT

2 minute read

IntelGenx’s Q4 And Full-Year 2022 Financials, ‘On The Cusp’ Of Rapid Growth?

By Lara Goldstein

March 30, 3:31 PM

Drug delivery company IntelGenx Technologies Corp. (OTCQB: IGXT)’s financial results for the three and twelve months ended December 31, 2022 show:

ATAI

1 minute read

Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today

By Benzinga Insights

January 30, 5:30 PM

GAINERS: LOSERS: Intelgenx Technologies (OTC:IGXT) shares closed down 7.06% at $0.23 Cybin (AMEX:CYBN) shares closed down 4.73% at…

ATAI

2 minute read

Cathie Wood Reacts To Atai’s Drastic Stock Plunge After Doomed Clinical Study Results

By Lara Goldstein

January 12, 12:20 PM

After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psyche

ATAI

2 minute read

Canadian Company’s New Version Of Chemo-Induced Pain Treatment Is On FDA Track

By Lara Goldstein

October 25, 1:47 PM

Drug delivery company IntelGenx Corp.

ATAI